ArticlePloS one2016
Enhanced Rice Blast Resistance by CRISPR/Cas9-Targeted Mutagenesis of the ERF Transcription Factor Gene OsERF922.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed, 3 syntheses or guidelines pooled it, 801 citations in OpenAlex.
- Pooled it
- Chickpea Biofortification for Cytokinin DehydrogenaseFrontiers in genetics · 2022Pooled it
- Conventional and new-breeding technologies for improving disease resistance in lentil (Frontiers in plant science · 2022Pooled it
- The CRISPR-dCas9 epigenetic toolbox: prospects for modulating gene expression in climate-resilient crops.Planta · 2026Review
- CRISPR/Cas9-Mediated Editing ofPlants (Basel, Switzerland) · 2026Article
- Harnessing CRISPR-Cas technology to enhance rice resilience under abiotic and biotic stress.Journal of applied genetics · 2026Review
- Enhanced Rice Yellow Mottle Virus Resistance via CRISPR/Cas9-Targeted Mutagenesis of the Rice eIF(iso)4G Gene.Molecular plant pathology · 2026Article
- Effects of CRISPR technology on agricultural sustainability: global applications and turkish perspective.Transgenic research · 2026Review
- Compact Cas12 Systems for Multiplex Engineering of Plant Abiotic-Stress Networks.Advanced genetics (Hoboken, N.J.) · 2026Article
- CRISPR/Cas Genome Editing and Its Applications in Cereal Crop Improvement.Plant-environment interactions (Hoboken, N.J.) · 2026Review
- Genome-wide identification of AP2/ERF transcription factors in Populus trichocarpa: structural analysis, expression patterns, and response to Melampsora larici-populina.BMC plant biology · 2026Article
- Unraveling plant immunity: from pathogen perception to resistance engineering.Science China. Life sciences · 2026Review
- CRISPR/Cas systems in fungal biotechnology: advancing high-value metabolite synthesis for industrial and food security applications.Archives of microbiology · 2026Review
- The emerging impact of CRISPR and gene editing on global crop improvement.Transgenic research · 2026Review
- Multiplex Gene Editing Creates Triple-Resistant Rice Against Both Insect Herbivores and Pathogens.Plants (Basel, Switzerland) · 2026Article
- Multiplex Editing ofInternational journal of molecular sciences · 2026Article
- Next-Generation Precision Breeding in Peanut (Insects · 2026Review
- From recalcitrance to precision: a robust regeneration, transformation and targeted gene editing framework inFrontiers in genome editing · 2026Article
- Genome Editing for Developing Disease-Resistant Plants.Methods in molecular biology (Clifton, N.J.) · 2026Article
- CRISPR-Cas technologies for precision genome editing in plants: advances, applications, and future perspectives.Frontiers in plant science · 2026Review
178 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rice blast is one of the most destructive diseases affecting rice worldwide. The adoption of host resistance has proven to be the most economical and effective approach to control rice blast. In recent years, sequence-specific nucleases (SSNs) have been demonstrated to be powerful tools for the improvement of crops via gene-specific genome editing, and CRISPR/Cas9 is thought to be the most effective SSN. Here, we report the improvement of rice blast resistance by engineering a CRISPR/Cas9 SSN (C-ERF922) targeting the OsERF922 gene in rice. Twenty-one C-ERF922-induced mutant plants (42.0%) were identified from 50 T0 transgenic plants. Sanger sequencing revealed that these plants harbored various insertion or deletion (InDel) mutations at the target site. We showed that all of the C-ERF922-induced allele mutations were transmitted to subsequent generations. Mutant plants harboring the desired gene modification but not containing the transferred DNA were obtained by segregation in the T1 and T2 generations. Six T2 homozygous mutant lines were further examined for a blast resistance phenotype and agronomic traits, such as plant height, flag leaf length and width, number of productive panicles, panicle length, number of grains per panicle, seed setting percentage and thousand seed weight. The results revealed that the number of blast lesions formed following pathogen infection was significantly decreased in all 6 mutant lines compared with wild-type plants at both the seedling and tillering stages. Furthermore, there were no significant differences between any of the 6 T2 mutant lines and the wild-type plants with regard to the agronomic traits tested. We also simultaneously targeted multiple sites within OsERF922 by using Cas9/Multi-target-sgRNAs (C-ERF922S1S2 and C-ERF922S1S2S3) to obtain plants harboring mutations at two or three sites. Our results indicate that gene modification via CRISPR/Cas9 is a useful approach for enhancing blast resistance in rice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.